Koselugo 10 mg Capsule

Koselugo 10 mg Capsule

Koselugo 10 mg Capsule contains the active ingredient selumetinib, which is used primarily for the treatment of neurofibromatosis type 1 (NF1) in pediatric patients with symptomatic, inoperable plexiform neurofibromas. Koselugo works by inhibiting specific enzymes known as MEK1 and MEK2, which are part of the signaling pathways that contribute to cell growth and proliferation. By targeting these enzymes, Koselugo helps reduce tumor size and alleviate related symptoms.

Uses

• Treatment of neurofibromatosis type 1 (NF1) in patients with inoperable plexiform neurofibromas.
• May be prescribed as part of a broader treatment plan to manage NF1 symptoms and tumor progression.

How Koselugo Works

Koselugo inhibits MEK1/2 enzymes within the MAPK pathway, disrupting abnormal cellular signaling responsible for tumor growth. This action can slow or reduce the growth of plexiform neurofibromas associated with NF1, improving the quality of life for affected patients.

Common Side Effects

• Gastrointestinal issues (e.g., diarrhea, nausea)
• Skin rashes or dryness
• Elevated liver enzymes
• Fatigue and muscle pain

Serious Side Effects (Seek Medical Attention)

• Heart problems, including decreased ejection fraction
• Vision changes or eye problems
• Severe skin reactions
• Gastrointestinal perforation

Key Features

• Contains selumetinib, a targeted therapy for NF1.
• Reduces tumor size and helps manage symptoms in children with inoperable plexiform neurofibromas.
• Administered orally, offering a convenient treatment option for patients.

Frequently Asked Questions (FAQ)

1. What is Koselugo used for?
   Koselugo is primarily used to treat children with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
2. How should I take Koselugo?
   Take Koselugo as directed by your healthcare provider, typically twice daily on an empty stomach.
3. Are there any dietary restrictions while on Koselugo?
   Avoid consuming grapefruit or grapefruit juice while taking this medication, as it can affect how the drug works.

References

1. AstraZeneca – Koselugo Product Information
   Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf
2. FDA Label for Koselugo
   Available from: https://www.nhs.uk/conditions/neurofibromatosis-type-1/